Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)

Michael J. Wagner, Megan Othus, Sandip P. Patel, Chris Ryan, Ashish Sangal, Benjamin Powers, G. Thomas Budd, Adrienne I. Victor, Chung Tsen Hsueh, Rashmi Chugh, Suresh Nair, Kirsten M. Leu, Mark Agulnik, Elad Sharon, Edward Mayerson, Melissa Plets, Charles Blanke, Howard Streicher, Young Kwang Chae, Razelle Kurzrock

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Article numbere002990
JournalJournal for immunotherapy of cancer
Volume9
Issue number8
DOIs
StatePublished - Aug 11 2021

ASJC Scopus Subject Areas

  • Immunology and Allergy
  • Immunology
  • Molecular Medicine
  • Oncology
  • Pharmacology
  • Cancer Research

Keywords

  • Clinical Trials
  • Combination
  • Drug Therapy
  • Immunotherapy
  • Phase II as Topic
  • Sarcoma

Cite this